Bicycle Therapeutics Wins FDA Orphan Drug Status for Nuzefatide in Pancreatic Cancer
Bicycle Therapeutics disclosed with its Q3 results that the FDA granted Orphan Drug Designation to nuzefatide pevedotin for pancreatic cancer in September. The EphA2-targeting Bicycle Drug Conjugate is in a Phase 2 trial in recurrent pancreatic ductal adenocarcinoma, with further updates expected in 2027. The designation is a regulatory status, not an approval.